23827
document
Addition of fexofenadine to inhaled corticosteroid therapy to reduce inflammatory biomarkers in atopic asthma . BACKGROUND We previously showed that H1-antihistamines may shift the PC20 ( provocation concentration that caused a decrease in forced expiratory volume in 1 second of 20 % ) threshold to adenosine monophosphate ( AMP ) challenge but may paradoxically prolong recovery . OBJECTIVES To measure AMP recovery using a constant predetermined AMP PC20 and to evaluate whether fexofenadine use confers add-on effects to treatment with either fluticasone propionate alone or combined fluticasone propionate-salmeterol . METHODS Fourteen atopic patients with mild-to-moderate asthma ( forced expiratory volume in 1 second of 76 % ) completed a double-blind , randomized , crossover study consisting of 3-week treatment blocks of either fluticasone propionate-salmeterol , 250 microg twice daily , or fluticasone propionate alone , 250 microg twice daily , in conjunction with either fexofenadine , 180 mg once daily , or matched placebo . Recovery after a predetermined AMP PC20 challenge was measured ( primary outcome ) , along with exhaled nitric oxide levels , plasma eosinophil cationic protein levels , peripheral eosinophil counts , pulmonary function , diary card outcomes , and quality of life ( all secondary outcomes ) . RESULTS There were no differences in any of the primary or secondary outcomes when fexofenadine was added to treatment with either fluticasone propionate-salmeterol or fluticasone propionate alone . The mean AMP recovery time was 25.0 vs 23.4 minutes for fexofenadine and placebo , respectively , as add-on to fluticasone-salmeterol and 22.5 vs 23.9 minutes , respectively , as add-on to fluticasone alone . CONCLUSION Fexofenadine did not affect recovery to a fixed dose of AMP challenge or any other surrogate inflammatory markers when given as add-on therapy to corticosteroid-treatedatopic asthmatic patients .
23828
Intervention_Pharmacological
fexofenadine
23829
Intervention_Pharmacological
inhaled corticosteroid therapy
23830
Intervention_Pharmacological
fexofenadine
23831
Intervention_Pharmacological
fluticasone propionate
23832
Intervention_Pharmacological
combined fluticasone propionate-salmeterol
23833
Intervention_Pharmacological
fluticasone propionate-salmeterol
23834
Intervention_Pharmacological
fluticasone propionate alone
23835
Intervention_Pharmacological
fexofenadine
23836
Intervention_Control
placebo
23837
Intervention_Pharmacological
fexofenadine
23838
Intervention_Pharmacological
fluticasone propionate-salmeterol
23839
Intervention_Pharmacological
fluticasone propionate
23840
Intervention_Pharmacological
fexofenadine
23841
Intervention_Control
placebo
23842
Intervention_Pharmacological
fluticasone-salmeterol
23843
Intervention_Pharmacological
fluticasone
23844
Intervention_Pharmacological
Fexofenadine
23845
Outcome_Physical
inflammatory biomarkers
23846
Outcome_Other
Recovery
23847
Outcome_Other
predetermined AMP PC20 challenge
23848
Outcome_Physical
exhaled nitric oxide levels
23849
Outcome_Physical
plasma eosinophil cationic protein levels
23850
Outcome_Physical
peripheral eosinophil counts
23851
Outcome_Physical
pulmonary function
23852
Outcome_Other
diary card outcomes
23853
Outcome_Mental
quality of life
23854
Participant_Condition
inflammatory biomarkers in atopic asthma .
23855
Participant_Sample-size
Fourteen atopic patients
23856
Participant_Condition
corticosteroid-treatedatopic asthmatic patients .